DWF has advised the AIM listed company SKIL Ports & Logistics Ltd in relation to a fundraising of up to £37.6 million.

The firm’s London-based corporate team advised on the placing, open offer and subscriptions which are expected to enable the company to continue the construction and build-out of a multi-purpose port and logistics park in the Karanja Creek region of India, near to Mumbai. It is forecasted that the port will be capable of receiving vessels by the end of this year and be fully operational by the end of the third quarter of 2017.

Advokatfirman Delphi has acted as legal advisor to NIBE Industrier AB (publ) in connection with NIBE’s rights issue of approximately SEK 3,024 million.

The subscription period in the rights issue expired on 25 October 2016. The interest in the rights issue has been high, and about 99.3 percent of the offered shares were subscribed for with subscription rights. Further, the rights issue was oversubscribed by approximately 54.6 percent of the offered shares of series B.

Clifford Chance is advising China Resources Pharmaceutical Group (CR Pharma) on its US$1.8 billion IPO and listing on the Hong Kong Stock Exchange. CR Pharma is a leading integrated pharmaceutical company in China engaged in the research and development, manufacturing, distribution and retail of an extensive range of pharmaceutical and other healthcare products. The joint sponsors on the deal are CCBI, CICC, Goldman Sachs and Merrill Lynch.

Ashurst has advised Euroz Securities Limited and Canaccord Genuity (Australia) Limited on a fully underwritten accelerated, non-renounceable entitlement offer by Cooper Energy Limited that will seek to raise up to A$62.6 million.

Euroz and Canaccord are acting as joint lead managers, bookrunners and underwriters to the Entitlement Offer (of 1 share for every existing 2 shares in Cooper at an issue price of $0.285).

Proceeds from the Entitlement Offer will be partially used to fund Cooper Energy's proposed acquisition of Santos Limited's Victorian gas assets.

Norton Rose Fulbright has advised Sumitomo Electric Bordnetze (SEBN) on its conversion into a European Stock Corporation (Societas Europaea, SE).

SEBN operates in the automotive industry and is a member of the Sumitomo Electric Industries Group. The multinational group includes approximately 389 subsidiaries and affiliates in more than 30 countries around the world, mainly in Asia, North America and Europe. The total number of employees for the entire group exceeds 240,000.

Davis Polk advised the underwriter, financial adviser and sponsor in connection with the underwritten renounceable rights offering of 48,110,637 new ordinary shares by Remgro Limited. The offering comprised a public offering in South Africa and private placements to institutional investors outside South Africa, including in the United States, and raised gross proceeds of approximately ZAR 9.3 billion ($675 million).

Davis Polk advised the dealer managers in connection with a cash tender offer by Koninklijke Philips N.V. to purchase up to $400 million aggregate principal amount of its outstanding 6.875% notes due 2038, 7.200% notes due 2026, 7.125% Series A debentures due 2025 and 7.750% Series B debentures due 2025.

Simpson Thacher recently represented Kyushu Railway Company (“JR Kyushu”), as issuer, and Japan Railway Construction, Transport and Technology Agency, as selling shareholder, in connection with JR Kyushu’s ¥416 billion (US$3.9 billion) initial public offering on the Tokyo Stock Exchange, including an international offering to institutional investors in reliance on Rule 144A and Regulation S.

CRISPR Therapeutics AG (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, announced on October 18, 2016 the pricing of its initial public offering of 4'000'000 common shares at a public offering price of $14.00 per share. CRISPR Therapeutics’ common shares have started trading on the NASDAQ Global Market under the ticker symbol "CRSP" on October 19, 2016. Citigroup, Piper Jaffray and Barclays acted as joint book-running managers for the offering. Guggenheim Securities acted as co-manager.

October 2016. ADC Therapeutics SA (ADCT), Lausanne, Switzerland, announced that it has raised USD 105 m through a private placement of shares. The financing was oversubscribed and supported by both new and existing investors, including Auven Therapeutics, the Wild Family Office and AstraZeneca. Since inception in 2012, ADCT has raised a total of USD 255 m in equity.

ADCT is an oncology drug development company that specializes in the development of proprietary antibody drug conjugates targeting major types of hematological malignancies and solid tumors.